summit therapeutics astrazeneca - Search News

News

Summit, AstraZeneca and Lung cancer

Reuters on MSN · 3d

Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.

Medical Dialogues · 1d

AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: Report

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a deal that could be worth up to USD 15 billion, according to a

Investopedia on MSN · 3d

Summit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership Talks

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.

2d

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

3don MSN

Why Summit Therapeutics Stock Soared 8% Higher Today

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results